Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
Special Offer: Just $199
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.23 (-1.51%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.23 (-1.51%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.23 (-1.51%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.23 (-1.51%)
NASDAQ:RYTM

Rhythm Pharmaceuticals - RYTM Stock Forecast, Price & News

$24.72
-0.10 (-0.40%)
(As of 11/28/2022 04:18 PM ET)
Add
Compare
Today's Range
$24.24
▼
$25.81
50-Day Range
$20.61
▼
$26.37
52-Week Range
$3.04
▼
$30.98
Volume
402,685 shs
Average Volume
1.21 million shs
Market Capitalization
$1.39 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$30.33

Rhythm Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
23.7% Upside
$30.33 Price Target
Short Interest
Bearish
17.43% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.80
Upright™ Environmental Score
News Sentiment
0.74mentions of Rhythm Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.60) to ($3.09) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.74 out of 5 stars

Medical Sector

898th out of 1,040 stocks

Pharmaceutical Preparations Industry

434th out of 509 stocks

See Top Rated MarketRank™ Stocks Here
RYTM stock logo

About Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, Smith-Magenis syndrome obesity, POMC epigenetic disorders, and other MC4R disorders. Rhythm Pharmaceuticals, Inc. has a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Receive RYTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RYTM Stock News Headlines

November 23, 2022 | msn.com
Sir Dave Dobbyn, Dizzee Rascal added as final headliners for Rhythm and Vines 2022
November 23, 2022 | americanbankingnews.com
Rhythm Pharmaceuticals (NASDAQ:RYTM) Shares Gap Down to $25.62
November 21, 2022 | finance.yahoo.com
Rhythm Pharmaceuticals Announces ▼IMCIVREE® (setmelanotide) Granted Marketing Authorization in Great Britain for Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome
November 11, 2022 | finance.yahoo.com
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Just Reported And Analysts Have Been Lifting Their Price Targets
November 10, 2022 | finance.yahoo.com
Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) Intrinsic Value Is Potentially 17% Below Its Share Price
November 8, 2022 | seekingalpha.com
Rhythm Pharmaceuticals, Inc. (RYTM) Q3 2022 Earnings Call Transcript
November 8, 2022 | finance.yahoo.com
Rhythm Pharmaceuticals Announces Publication of Results from Phase 3 Clinical Trial of IMCIVREE® (setmelanotide) in Bardet-Biedl Syndrome in The Lancet Diabetes and Endocrinology
November 8, 2022 | finance.yahoo.com
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q3 Loss, Lags Revenue Estimates
November 8, 2022 | finance.yahoo.com
Rhythm Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Update
November 3, 2022 | finance.yahoo.com
Rhythm Pharmaceuticals Announces 11 Presentations at The Obesity Society’s Annual Meeting at ObesityWeek®
November 2, 2022 | finance.yahoo.com
Rhythm Pharmaceuticals Presents Data from Phase 2 and Long-term Extension Trials Evaluating Setmelanotide for the Treatment of Hypothalamic Obesity at ObesityWeek® and Plans to Initiate Phase 3 Trial in Early 2023
November 1, 2022 | finance.yahoo.com
Rhythm Pharmaceuticals Announces Setmelanotide Granted Breakthrough Therapy Designation for Hypothalamic Obesity by the U.S. FDA
October 25, 2022 | finance.yahoo.com
Rhythm Pharmaceuticals to Present Full Data from Phase 2 Clinical Trial Evaluating Setmelanotide in Hypothalamic Obesity at ObesityWeek® 2022
October 25, 2022 | finance.yahoo.com
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q3 Earnings Expected to Decline
October 18, 2022 | finance.yahoo.com
Is Rhythm Pharmaceuticals (NASDAQ:RYTM) In A Good Position To Deliver On Growth Plans?
October 12, 2022 | finance.yahoo.com
Rhythm Pharmaceuticals Convenes Inaugural International Meeting on Pathway-Related Obesity: Vision of Excellence (IMPROVE) 2022
October 10, 2022 | seekingalpha.com
Rhythm Pharmaceuticals: Revisiting The Investment Thesis
October 7, 2022 | msn.com
Review: Taiko no Tatsujin Rhythm Festival is a ‘DON-derful’ treat - Technobubble Gaming
October 6, 2022 | finance.yahoo.com
Rhythm Pharmaceuticals Appoints Dana Washburn, M.D., as Senior Vice President of Clinical Development
September 23, 2022 | benzinga.com
Rhythm Pharmaceuticals Announces Publication of Children's Book for Patients and Families Living with Bardet-Biedl Syndrome (BBS)
September 23, 2022 | finance.yahoo.com
Rhythm Pharmaceuticals Announces Publication of Children’s Book for Patients and Families Living with Bardet-Biedl Syndrome (BBS)
September 19, 2022 | finance.yahoo.com
Rhythm Pharmaceuticals, Inc. Announces Closing of $124.8 Million Public Offering
September 19, 2022 | finance.yahoo.com
Rhythm Pharmaceuticals, Inc.'s (NASDAQ:RYTM) large institutional owners must be happy as stock continues to impress, up 4.0% over the past week
September 19, 2022 | finance.yahoo.com
Rhythm Pharmaceuticals Presents New Disease Burden Findings and Analyses of Setmelanotide Data in Children and Adolescents with Rare MC4R Pathway Diseases at ESPE 2022
September 15, 2022 | seekingalpha.com
Hot Stocks: FTCI and WYNN both gain, ADBE falls on acquisition news, RYTM drops more than 10%
See More Headlines
Receive RYTM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Rhythm Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RYTM Company Calendar

Last Earnings
11/08/2022
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/07/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RYTM
CUSIP
N/A
CIK
1649904
Web
www.rhythmtx.com
Phone
(857) 264-4280
Fax
857-264-4299
Employees
140
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$30.33
High Stock Price Forecast
$37.00
Low Stock Price Forecast
$20.00
Forecasted Upside/Downside
+22.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
8 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.58)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-69,610,000.00
Net Margins
-1,089.07%
Pretax Margin
-1,137.00%
Return on Equity
-72.83%
Return on Assets
-56.64%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
10.93
Quick Ratio
10.93

Sales & Book Value

Annual Sales
$3.15 million
Price / Sales
442.20
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$5.65 per share
Price / Book
4.38

Miscellaneous

Outstanding Shares
56,348,000
Free Float
54,207,000
Market Cap
$1.39 billion
Optionable
Optionable
Beta
1.98

Key Executives

  • Dr. David P. Meeker M.D. (Age 68)
    Chairman, Pres & CEO
    Comp: $1.09M
  • Mr. Hunter C. Smith M.B.A. (Age 53)
    CFO & Treasurer
    Comp: $658.21k
  • Mr. Joseph Shulman (Age 47)
    Chief Technical Officer
    Comp: $555.66k
  • Mr. Yann Mazabraud (Age 49)
    Exec. VP & Head of International
    Comp: $693.62k
  • Ms. Jennifer L. Chien (Age 47)
    Exec. VP & Head of North America
    Comp: $597.46k
  • Mr. William T. Roberts (Age 43)
    Chief Accounting Officer
  • Mr. David Connolly
    Head of Investor Relations & Corp. Communications
  • Mr. Jim Flaherty
    Sr. VP & Gen. Counsel
  • Ms. Sarah Ryan
    VP of Sales & Marketing
  • Ms. Pamela J. Cramer (Age 48)
    Chief HR Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













RYTM Stock - Frequently Asked Questions

Should I buy or sell Rhythm Pharmaceuticals stock right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rhythm Pharmaceuticals in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RYTM shares.
View RYTM analyst ratings or view top-rated stocks.

What is Rhythm Pharmaceuticals' stock price forecast for 2023?

8 equities research analysts have issued 1 year price targets for Rhythm Pharmaceuticals' stock. Their RYTM share price forecasts range from $20.00 to $37.00. On average, they predict the company's share price to reach $30.33 in the next twelve months. This suggests a possible upside of 22.5% from the stock's current price.
View analysts price targets for RYTM or view top-rated stocks among Wall Street analysts.

How have RYTM shares performed in 2022?

Rhythm Pharmaceuticals' stock was trading at $9.98 at the start of the year. Since then, RYTM shares have increased by 148.1% and is now trading at $24.76.
View the best growth stocks for 2022 here.

When is Rhythm Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 7th 2023.
View our RYTM earnings forecast.

How were Rhythm Pharmaceuticals' earnings last quarter?

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) issued its earnings results on Tuesday, November, 8th. The company reported ($0.79) earnings per share for the quarter, topping the consensus estimate of ($1.01) by $0.22. The firm earned $4.28 million during the quarter, compared to analysts' expectations of $5.36 million. Rhythm Pharmaceuticals had a negative trailing twelve-month return on equity of 72.83% and a negative net margin of 1,089.07%.

What other stocks do shareholders of Rhythm Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rhythm Pharmaceuticals investors own include VBI Vaccines (VBIV), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Viking Therapeutics (VKTX), Amarin (AMRN), Kadmon (KDMN), Pfizer (PFE), Sangamo Therapeutics (SGMO) and Sarepta Therapeutics (SRPT).

When did Rhythm Pharmaceuticals IPO?

(RYTM) raised $100 million in an initial public offering on Thursday, October 5th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, BofA Merrill Lynch and Cowen acted as the underwriters for the IPO and Needham was co-manager.

What is Rhythm Pharmaceuticals' stock symbol?

Rhythm Pharmaceuticals trades on the NASDAQ under the ticker symbol "RYTM."

Who are Rhythm Pharmaceuticals' major shareholders?

Rhythm Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (12.47%), Federated Hermes Inc. (11.19%), RA Capital Management L.P. (9.71%), BlackRock Inc. (6.28%), State Street Corp (5.55%) and Vanguard Group Inc. (3.97%). Insiders that own company stock include David P Meeker, Hunter C Smith, Joseph Shulman, Nithya Desikan, Pamela J Cramer, Ra Capital Management, LP, Todd Foley, William T Roberts and Yann Mazabraud.
View institutional ownership trends.

How do I buy shares of Rhythm Pharmaceuticals?

Shares of RYTM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rhythm Pharmaceuticals' stock price today?

One share of RYTM stock can currently be purchased for approximately $24.76.

How much money does Rhythm Pharmaceuticals make?

Rhythm Pharmaceuticals (NASDAQ:RYTM) has a market capitalization of $1.40 billion and generates $3.15 million in revenue each year. The company earns $-69,610,000.00 in net income (profit) each year or ($3.58) on an earnings per share basis.

How many employees does Rhythm Pharmaceuticals have?

The company employs 140 workers across the globe.

How can I contact Rhythm Pharmaceuticals?

Rhythm Pharmaceuticals' mailing address is 222 BERKELEY STREET 12TH FLOOR, BOSTON MA, 02116. The official website for the company is www.rhythmtx.com. The company can be reached via phone at (857) 264-4280, via email at hannah.deresiewicz@sternir.com, or via fax at 857-264-4299.

This page (NASDAQ:RYTM) was last updated on 11/28/2022 by MarketBeat.com Staff